TY - JOUR
T1 - Tumor-Treating Fields
T2 - A fourth modality in cancer treatment, new practice updates
AU - Arvind, Rhea
AU - Chandana, Sreenivasa R.
AU - Borad, Mitesh J.
AU - Pennington, Danniel
AU - Mody, Kabir
AU - Babiker, Hani
N1 - Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/12
Y1 - 2021/12
N2 - Although major innovations in treatment are advancing, cancer persists as one of the leading causes of mortality. With the rising incidence of cancer and as we treat them, patients incur short term and long-term toxicities of current traditional therapies, including chemotherapy. This imposes a significant physical, emotional, and financial burden among patients, which affects their quality of life. Tumor-Treating Fields (TTFields) is a novel innovative new treatment modality that utilizes alternating electric fields at specific intermediate frequencies to diminish tumor growth by inhibiting mitosis and thus proliferation of malignant cells. The distinguishing feature of this new treatment modality is that it is noninvasive and tolerable. In fact, TTFields is currently FDA approved for the treatment of glioblastoma multiforme (GBM) as well as malignant pleural mesothelioma (MPM). Recently, TTFields have also been found to affect immunogenic cell death resulting in stronger anti-neoplastic effects. In this review, we discuss the mechanism of action of TTFields, the plethora of clinical trials being conducted in patients with GBM, pancreatic adenocarcinoma, ovarian cancer, non-small-cell-lung-cancer (NSCLC), brain metastasis from NSCLC, and MPM and toxicity profile.
AB - Although major innovations in treatment are advancing, cancer persists as one of the leading causes of mortality. With the rising incidence of cancer and as we treat them, patients incur short term and long-term toxicities of current traditional therapies, including chemotherapy. This imposes a significant physical, emotional, and financial burden among patients, which affects their quality of life. Tumor-Treating Fields (TTFields) is a novel innovative new treatment modality that utilizes alternating electric fields at specific intermediate frequencies to diminish tumor growth by inhibiting mitosis and thus proliferation of malignant cells. The distinguishing feature of this new treatment modality is that it is noninvasive and tolerable. In fact, TTFields is currently FDA approved for the treatment of glioblastoma multiforme (GBM) as well as malignant pleural mesothelioma (MPM). Recently, TTFields have also been found to affect immunogenic cell death resulting in stronger anti-neoplastic effects. In this review, we discuss the mechanism of action of TTFields, the plethora of clinical trials being conducted in patients with GBM, pancreatic adenocarcinoma, ovarian cancer, non-small-cell-lung-cancer (NSCLC), brain metastasis from NSCLC, and MPM and toxicity profile.
KW - Cancer
KW - Electric fields
KW - Glioblastoma
KW - Microtubule
KW - Mitosis
KW - Modality
KW - Oncology
KW - Overall survival
KW - Progression free survival
KW - Toxicity profile
KW - Treatment
KW - Tumor
UR - http://www.scopus.com/inward/record.url?scp=85119479236&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119479236&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2021.103535
DO - 10.1016/j.critrevonc.2021.103535
M3 - Review article
C2 - 34808377
AN - SCOPUS:85119479236
SN - 1040-8428
VL - 168
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103535
ER -